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Abstract
Background: Louse-borne relapsing fever (LBRF) is a neglected disease that has been restricted to East Africa for
many decades. Several cases in refugees from the Horn of Africa have been recently diagnosed in four European
countries.
Case presentation: We report four additional cases of LBRF in asylum seekers from Somalia and Eritrea who
presented with fever shortly after arriving in Switzerland during a seven-month period. Multiple spirochetes were
visualized on stained blood films which were identified as Borrelia recurrentis by 16S rRNA gene sequencing. All
patients recovered after antibiotic treatment with ceftriaxone and/or doxycycline. Concurrent infections (malaria
and tuberculosis) were diagnosed in half of our patients. Possible modes of transmission and preventive measures
are discussed.
Conclusions: These reported cases highlight the ongoing transmission of LBRF in migrants from East Africa.
Diagnosis of LBRF cases and prevention of autochthonous transmission in asylum seeker camps are important
steps for the near future.
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Background
Once a major epidemic disease in Africa and Eurasia,
louse-borne relapsing fever (LBRF) caused by Borrelia
recurrentis has been restricted to East Africa for many
decades with most cases reported from Ethiopia [1, 2].
This neglected disease is exclusively transmitted from
human to human via the human body louse Pediculus
humanus humanus, which is linked to areas of over-
crowding, war, and destitution [3]. Due to its restricted
geographical occurrence und non-specific presentation
with fever and body pain resembling other serious infec-
tions such as malaria, viral hemorrhagic fever, leptospir-
osis or typhoid fever, the diagnosis of LBRF might be
missed in non-endemic countries. Of note, mortality in
untreated patients may be substantial (up to 70 %) [1].
Diagnosis is established by demonstration of spirochetes
in stained blood films during febrile episodes, and
polymerase chain reaction (PCR) targeting the 16S
rRNA gene may be used for confirmation [4]. Treatment
of choice is a single dose of procaine penicillin, tetracyc-
line or doxycycline, and patients should be closely moni-
tored for a potentially severe Jarisch-Herxheimer
reaction [3, 5].
In the context of an ongoing influx of refugees from
East Africa into Europe, more than twenty cases of LBRF
in asylum seekers originating from this area have been
recently reported from several European countries [6–9]
including the first case diagnosed in Switzerland [4] at
one of our institutions. Herein, we report four add-
itional, independent cases of LBRF in asylum seekers
from the Horn of Africa at our three institutions during
a five month period. All participants gave written
informed consent for publication of their details and
images.
Case presentation
LBRF patients originated from Eritrea and Somalia, re-
spectively, with a final common travel route via Sudan,
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Libya and Italy before arriving in Switzerland in June to
December 2015. All patients were referred to the emer-
gency department of our three institutions with fever
and other non-specific complaints shortly (one to seven
days) after arrival. Interestingly, all patients reported a
previous febrile episode in Italy or Libya. Important clin-
ical characteristics of the patients are shown in the
Table 1. All patients denied a significant past medical
history or past/current medical treatment. With the ex-
ception of enlarged cervical and axillary lymph nodes in
patient 3, physical examination was essentially non-
specific and consistent with sepsis of unknown origin in
the context of fever, tachycardia and hypotension. Rou-
tine blood tests were significant for mild to moderate
thrombocytopenia, mild anaemia and markedly elevated
inflammatory markers in all cases (Table 1). In addition,
one patient showed evidence of haemolysis with an in-
creased LDH and bilirubin. Differential diagnosis enter-
tained by the treating clinicians included bacterial sepsis
of unknown origin, typhoid fever and malaria in all pa-
tients, and primary EBV infection in patient 3. Two sets
of blood cultures, stained blood smears and a malaria
rapid diagnostic test were ordered in all patients. Diag-
nosis of Borrelia-associated relapsing fever was estab-
lished by demonstration of abundant extracellular
spirochetes in stained blood films (Fig. 1). Additional
work-up including blood cultures and malaria tests was
negative in patients 1 and 3, and positive for Mycobac-
terium tuberculosis lymphadenitis (lymph node biopsy
demonstrating acid fast bacilli on auramine staining and
isolation of M. tuberculosis from culture) and Plasmo-
dium falciparum malaria (P. falciparum parasites were
observed concomitantly with spirochetes in stained
blood films) in patients 2 and 4, respectively. The first
two patients were admitted to the intensive-care unit for
supportive treatment of sepsis-related hypotension and
were started on intravenous ceftriaxone, whereas the last
two patients received doxycycline (in addition to stand-
ard first-line anti-tuberculous treatment in patient 2 and
artemether/lumefantrine in patient 4 for concurrent
Plasmodium falciparum malaria) and were admitted to
the general medical ward after fluid resuscitation. All
patients rapidly recovered after antibiotic treatment.
Treatment duration was longer than necessary for LBRF
to cover for potential tick-borne relapsing fever, as con-
firmation of LBRF by PCR was not available immediately.
A Jarisch-Herxheimer reaction including aggravated
hypotension, tachycardia and high-grade fever was only
observed in patient 2.
Subsequently, diagnosis of LBRF was confirmed in all
cases by broad-range bacterial PCR followed by sequen-
cing of the first half of the 16S rRNA gene using EDTA
blood specimens that were positive for spirochetes on
microscopy (100 % identity to B. recurrentis reference
sequence). Based on this result we analysed the entire 16S
rRNA gene in two patients, which yielded 1475- (patient
1) and 1480-bp-long (patient 3) sequences (GenBank ac-
cession no. KT221542 and KU308247), respectively, with
100 % identity each to B. recurrentis reference strain A1
(using the Basic Local Alignment Search Tool (BLAST),
National Library of Medicine) [10].
LBRF was once a major epidemic disease in many
parts of the world [1]. Lack of an animal reservoir,
exclusive transmission of the infectious agent B.
recurrentis via the human body louse and the associ-
ation of the latter with poor hygienic conditions dur-
ing war and destitution are obvious explanations for
the fact that LBRF has been rarely encountered in
Europe since World War II.
Interestingly, this almost forgotten disease has re-
emerged in Europe in the context of the ongoing migra-
tion from East Africa. Since July 2015, 26 cases of LBRF
in migrants from the Horn of Africa have been reported
from four European countries including the Netherlands
[9] (two refugees from Eritrea), Germany (15 refugees
from Somalia (12), Eritrea (2) and Ethiopia (1)) [8], Italy
(eight refugees from Somalia) [6, 7] and Switzerland
(one refugee from Eritrea) [4]. Herein, we report four
additional cases of LBRF in refugees from Eritrea and
Somalia. As symptoms of LBRF are non-specific and a
blood-smear is required to diagnose LBRF, these cases
may only represent the tip of the iceberg and further
cases are expected. The fact that our last patient was
only diagnosed in December 2015 confirms ongoing
transmission of LBRF in migrants from East Africa and
underscores the requirement for continuous vigilance
and surveillance for this disease in the future months or
even years.
Given the long duration of travel and the short incuba-
tion period (2–15 days), infection with B. recurrentis did
most likely not occur in the country of origin, but along
migration routes. All our patients reported a previous fe-
brile episode while travelling through Libya or Italy,
which might or might not have been related to LBRF,
and one patient even remembered an infestation with
body lice during a prison stay in Libya. While most pre-
viously reported cases travelled via Sudan and Libya to
Italy, the exact mode and location of transmission
remains to be determined, but might include spread of
Ethiopian foci of LBRF infection into neighbouring
countries such as Sudan or introduction of LBRF into
camps and shelters in Sudan, Libya or even Italy by
migrants after transit of LBRF-endemic Ethiopia. Joint
travel of refugees with body lice infested migrants in
confined spaces on boats across the Mediterranean Sea
might facilitate the spread of LBRF to camps in Europe.
This hypothesis is underscored by a recent Italian report
of LBRF in two Somalian refugees, who had not travelled
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Table 1 Characteristics of four patients suffering from louse-borne relapsing fever (Borrelia recurrentis) diagnosed in Switzerland from June to December 2015







Other laboratory features Treatment
1 M, 25 y Eritrea ER, SU, LB,
IT, CH
Libya Fever, abdominal pain,
epistaxis
56, 30 312, 312 Mild anemia, hyponatremia
and hypokalemia
Ceftriaxone for 2 days
followed by doxycycline
for 7 days
2 M, 29 y Somalia SO, KE, SU,
LB, IT, CH
Italy (infestation with
body lice in Libya)
Fever, abdominal pain,
headache, muscle aches
141, 54 245, 245 Mild anemia, leukocytosis
and hyponatremia
Ceftriaxone for 1 day
followed by doxycycline
for 7 days plus
HRZEb
3 F, 21 y Somalia SO, KE, UG,
SU, LB, IT,
CH
Italy Fever, pollakisuria, swollen/
painful cervical/axillary
lymphadenopathy
45, 27 367, 367 Mild anemia, leukocytosis
and hyponatremia, elevated
creatinine (mild), bilirubin
and LDH (both moderate)
Doxycycline for 5 days
4 M, 17y Somalia SO, ET, SU,
LB, IT, CH
Libya Fever, chills, cough,
urinary incontinence
167, 62 127, 235 Moderate anemia, mild
hyponatremia, hypokalemia,
elevated creatinine and LDH
(both mild)
Doxycycline for 3 days
plus Artemether/
lumefantrinea
Abbreviations: F female, M male, Y year, CRP C-reactive protein, HRZE antimycobacterial treatment with isoniazid (H), rifampicin (R), pyrazinamide (Z) and ethambutol (E)
Travel route: CH Switzerland, ER Eritrea, ET Ethiopia, IT Italy, LB Libya, SU Sudan, SO Somalia, UG Uganda
Platelet count, norm: 150–450 × 109/L; C-reactive protein, norm: <10 mg/L
aArtemether/lumefantrine treatment was administered for concurrent Plasmodium falciparum malaria infection














outside of Italy for several years, but had resided in the
same facility as three recently arrived asylum seekers
who were diagnosed with LBRF during the same period
of time (July-September 2015) [7]. Hence, introduction
and autochthonous transmission of infected body lice
and consequently LBRF in asylum seeker facilities in
North African or European transit countries seem pos-
sible and may pose a challenge for the near future.
Nevertheless, it is intriguing, that LBRF infections have
not yet been reported in asylum seekers from other parts
of Africa, although migration routes partially overlap
and often converge in Sudan, Libya or Italy, or from the
Middle East (including refugees from Syria). In conclu-
sion, transmission of body lice infected with B. recurren-
tis along migration routes, in particular in Libya, during
the passage of the Mediterranean Sea and in Italy seems
most likely, in our opinion, but future epidemiological
studies are necessary to determine the exact location of
transmission.
Given the ongoing migration of asylum seekers
from East Africa into Europe, physicians should be
vigilant and consider the possibility of LBRF, other
louse-transmitted diseases such as epidemic typhus
and trench fever, and non-louse-transmitted diseases
such as malaria, tuberculosis and typhoid fever when
assessing febrile migrants [3]. Concomitant serious,
non-louse-transmitted diseases were diagnosed in half
of our patients.
As diagnosis of LBRF is established by demonstra-
tion of spirochetes in stained blood films during
febrile episodes, haematologists need to be aware of
this “forgotten” disease. Immediate treatment with
procaine penicillin, an intravenous cephalosporin or
an oral tetracycline is mandatory. In addition, infec-
tion control and prevention measures are crucial to
prevent lice transmission in asylum seeker camps in
North Africa and Europe. These may include hot
washing (60 °C) or preferably exchange of clothes in
addition to screening for lice infestation at arrival and
preventive delousing of individuals living in close
proximity with a case. Complete exchange of clothes
is particularly effective, as body lice live in garments
(and not on the human skin) and do not survive un-
less they feed on the blood of human beings every
single day [3]. The European Centre for Disease Pre-
vention and Control has issued guidance for infection
control measures that should be implemented in the
case of LBRF diagnosis [11].
Conclusions
The future will tell if the almost forgotten disease LBRF
will spread to other parts of Africa and Europe in the
context of the ongoing migration including refugees
from the Middle East. Diagnosis of LBRF cases and pre-
vention of autochthonous transmission in asylum seeker
camps are crucial steps for the near future.
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Fig. 1 Microscopic detection of spirochetes (black arrows) in blood
from patient 2. May-Grünwald Giemsa (MGG)-stained blood smear,
1000-fold magnification
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